Tag Archives | immuno-oncology

Large Cap Biopharma Earnings Boost Stocks: Update 8/1/17

Rayno Large Cap Biopharma Earnings Summary 8/1/17 Biotech Stocks Hit Highs in Mid-July up 18%, 30% on XBI (Click on “urls” below for Company Press Release) All the large cap biopharmaceutical earnings have come in except Regeneron (REGN) which will report on August 3.  Stocks were broadly higher in July after financial reports, however we suggested […]

Continue Reading 0

Rayno BioBeat #4: Biotechs Weaken on Profit Taking…Update-2

Update-2 7/31 After Close: Biotechs Remain Weak But No Sell Signal As we track the XBI over the past 5 days we are about 3.2% off highs from $82 down to $78.17. Although the XBI has been our top ETF pick since January 2017 we recently put new buys on hold and suggested last week […]

Continue Reading 0

Hot Fun in the Summertime: NYC Hits 92 degrees;Healthcare Plan Draft Out

Update after close 7/13: Health Care draft bill appears to have stabilized biotech despite opposition. ETFs end in green but XLV is flat. More analysis is coming tomorrow. ========= It’s Vacation Time We are out on vaca until Monday the 17th. Here are some updates as of 11:15a Thursday: Biotechs are weak today falling below […]

Continue Reading 0

2017 Life Science Review #1: Big Biotech Gains for First Half

Big Biotech Gains for Stocks in First Half Rayno Life Science Picks Top Winners YTD: Foundation Medicine (FMI) up 124.6%, bluebird bio (BLUE) up 70.26%, XBI up 20.9%. Large cap winners since inception: Abbvie (ABBV) and Roche ADR (RHHBY). 6/27 Take some profits on XBI at $78. XBI is our top ETF pick. XLV SPDR […]

Continue Reading 0

BIO 2017 International #1: CAR-T Therapies on Solid Tumors

CAR-T Therapies on Solid Tumors Here is an excellent summary by BIOtechNow Editors on the application of CAR-T (Chimeric Antigen Receptor) T-Cell therapies on solid tumors. Up until now CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Here are some of the major companies engaged in CAR-T: Bellicum Pharmaceuticals (BLCM), […]

Continue Reading 0

BIOtech Breakout: Healthcare Stocks Lead the Way…Update-1

6/27/17 Red Screen Day: Sell-Off in Biotechs Possibly Due to Senate Delay in Healthcare Vote IBB down 1.54% at $314.80. Momentum stocks are weak; NASDAQ down 1.2%. Take profits on XBI trade at $78 range after 34% move YTD. Allow time for arm twisting by Republicans after JY 4. ======== Biotech Breakout Continues with Larger […]

Continue Reading 0

Good Day Today: XBI Breaks Through to YTD Highs…Update

Market Update 12n 6/20: Biotechs Continue to Rally IBB up 1.87% to $305.50; XBI up 1.93% to $75.60 As we have covered biotech ETFs in the past the XBI is one of our core positions for aggressive investors. It outperforms because of equally weighted positions where a big move in several mid or small caps […]

Continue Reading 0

ASCO Update #2: Stock Performance Data as of 6/8/17

ASCO Update: Many Stocks Rallied on the News Over the Past Month ASCO Rally is Holding but Fails to Break Through to New 2017 Highs The stock performance of most companies with ASCO news is summarized below.Biotechnology stocks are driven by clinical and deal news so here are some trends to consider: Anticipation of positive […]

Continue Reading 0

ASCO Update: Movers on the News-INCY PBYI RHHBY

June 5…ASCO Update: Incyte Puma and Roche A lot of the product news is already “baked into” stock prices but here is a brief summary of big movers today on clinical news updates. The bellwether XBI peaked at $71.72 today and is down 0.62% to $70.66. bluebird bio (BLUE) up 8.5% to $91.30 BLUE soared […]

Continue Reading 0

Biotechs Sink Again in Sector Shift to Technology Stocks: Update-1

6/1/17 Update at close…Biotechs Bounce off Bottom of 3 Month Trading Range IBB up 1.8% back above $290 after hitting 200 SMA bottom. XBI up 2.7% to $69.54 at SMA 50. XBI 2017 top is $72. XLV a safer play up over 1% to $76.91; above March highs and near 12 mo. highs up 11.58% […]

Continue Reading 0